← Back to headlines
Corcept Therapeutics Faces Setback in Korlym Patent Dispute with Teva
Corcept Therapeutics' stock declined after an appeals court ruled in favor of Teva Pharmaceuticals in a patent dispute concerning Corcept's drug Korlym.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Trump Administration Pushes Washington Arch Project and Mail Voting Rules
19m ago
US Investigates Deadly Strike on Iranian Wedding Linked to American Munitions
25m ago
Japan Household Spending Falls for Eighth Consecutive Month Amid Rising Prices
39m ago
South Korea Prepares Military Deployment Near Strait of Hormuz Amid Regional Tensions
47m ago